Mirati offers look at highly anticipated data on KRAS-blocking cancer drug

Mirati offers look at highly anticipated data on KRAS-blocking cancer drug

STAT Plus: Mirati takes a turn at the podium with a first look at its KRAS-blocking cancer drug

By ADAM FEUERSTEIN

ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME

The first-in-human clinical data for the drug, called MRTX849, are scant — encompassing only 12 patients — but they are also significant.

READ MORE